Actinium-225 PSMA I&T Composition for Stable Low-Toxicity Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic castration-resistant prostate cancer (mCRPC) using 177Lu-PSMA radioligand therapy (RLT) and 225Ac-PSMA targeted alpha therapy (TAT) suffer from high hematological and salivary gland toxicity, limiting their widespread application.
Innovation Solution
A radiopharmaceutical composition comprising actinium-225 (225Ac)-PSMA I&T, formulated with ascorbic acid and hydrochloric acid, offering improved shelf-life stability and low toxicity profiles, with radiochemical purity and stability maintained for up to 120 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody treatments (177Lu-PSMA mAb J591) are used for targeted radionuclide therapy, then tumor targeting capability is improved, but hematological toxicity increases significantly
Solution Approach 1:
The patent replaces monoclonal antibodies with small molecule inhibitors (PSMA-617 and PSMA I&T) that have shorter circulation times and are cleared more rapidly from the body. This substitution maintains tumor targeting effectiveness while significantly reducing the duration of exposure to healthy tissues, thereby lowering hematological toxicity. The small molecules are effectively 'disposable' compared to the persistent monoclonal antibodies.
Solution Approach 2:
The patent changes the molecular size parameter from large monoclonal antibodies to small molecule inhibitors, and alters the pharmacokinetic parameters including circulation half-life and clearance rate. These parameter changes result in reduced accumulation in bone marrow and other healthy tissues, directly addressing the hematological toxicity issue while preserving therapeutic efficacy.
2Power
If actinium-225 radiopharmaceuticals are used for targeted alpha therapy, then therapeutic efficacy is improved, but salivary gland toxicity increases
Solution Approach 1:
The patent modifies the chemical structure parameters of the radiopharmaceutical by using different chelating agents and linker structures in the small molecule inhibitors. These structural parameter changes alter the biodistribution pattern, reducing uptake in salivary glands while maintaining high affinity binding to PSMA on tumor cells. The modified molecular parameters achieve selective tumor targeting with reduced off-target effects.
3Object-affected harmful factors
If small molecule inhibitors (PSMA-617, PSMA I&T) are used instead of monoclonal antibodies, then hematological toxicity is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the radiopharmaceutical development into modular components: standardized small molecule cores (PSMA-617, PSMA I&T), interchangeable chelating agents, and flexible linking structures. This segmentation allows for simplified manufacturing processes where components can be produced separately and assembled, reducing overall manufacturing complexity despite the advanced chemistry required.
4Duration of action of stationary object
If radiopharmaceutical compositions are formulated for long-term stability, then shelf-life is improved, but radiochemical purity may deteriorate over time
Solution Approach 1:
The patent employs preliminary stabilization measures during the formulation stage, including optimization of pH buffers, selection of appropriate excipients, and pre-validation of storage conditions. These preliminary actions ensure that the radiopharmaceutical maintains radiochemical purity throughout the intended shelf-life, preventing degradation before administration. The formulation is designed from the outset to be stable, rather than attempting to stabilize it after degradation begins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides effective targeted radionuclide therapy for mCRPC with reduced adverse effects, demonstrating improved radiochemical stability and lower toxicity compared to monoclonal antibody treatments.
Implementation Method 1
actinium-225 (225Ac)-PSMA I&T, formulated with ascorbic acid and hydrochloric acid, offering improved shelf-life stability and low toxicity profiles
Data Source
AI summary
The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.